Precision Medicine in Neurodegenerative Disorders
-10%
portes grátis
Precision Medicine in Neurodegenerative Disorders
Part I
Espay, Alberto J.
Elsevier - Health Sciences Division
06/2023
288
Dura
Inglês
9780323855389
15 a 20 dias
Descrição não disponível.
Part 1 Conceptual Framework
1. The definition of precision medicine in neurodegenerative disorders and the one disease-many-diseases tension
2. Models of precision medicine for neurodegeneration
3. Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration
4. Mixed pathology as a rule, not exception: Time to reconsider disease nosology?
5. Neurodegenerative disorders: From clinicopathology convergence to systems biology divergence
6. The emergence of genotypic divergence and future precision medicine applications
7. Lessons from other fields of medicine, Part 1: Breast cancer
8. Lessons from other fields of medicine, Part 2: Cystic fibrosis
9. Lessons learned from evolving frameworks in adult glioblastoma
Part 2 Pitfalls in Definitions, Cohorts, and Measures of Progression
10. Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
11. The theoretical problems of "prodrome? and "phenoconversion? in neurodegeneration
12. The dilemma between milestones of progression vs. clinical scales in Parkinson disease
13. Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer Disease and synucleinopathies
14. Challenges in the study of individuals at risk for Parkinson disease
15. The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms
1. The definition of precision medicine in neurodegenerative disorders and the one disease-many-diseases tension
2. Models of precision medicine for neurodegeneration
3. Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration
4. Mixed pathology as a rule, not exception: Time to reconsider disease nosology?
5. Neurodegenerative disorders: From clinicopathology convergence to systems biology divergence
6. The emergence of genotypic divergence and future precision medicine applications
7. Lessons from other fields of medicine, Part 1: Breast cancer
8. Lessons from other fields of medicine, Part 2: Cystic fibrosis
9. Lessons learned from evolving frameworks in adult glioblastoma
Part 2 Pitfalls in Definitions, Cohorts, and Measures of Progression
10. Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
11. The theoretical problems of "prodrome? and "phenoconversion? in neurodegeneration
12. The dilemma between milestones of progression vs. clinical scales in Parkinson disease
13. Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer Disease and synucleinopathies
14. Challenges in the study of individuals at risk for Parkinson disease
15. The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
precision medicine; neurodegenerative disease; Movement disorders; Parkinson's
Part 1 Conceptual Framework
1. The definition of precision medicine in neurodegenerative disorders and the one disease-many-diseases tension
2. Models of precision medicine for neurodegeneration
3. Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration
4. Mixed pathology as a rule, not exception: Time to reconsider disease nosology?
5. Neurodegenerative disorders: From clinicopathology convergence to systems biology divergence
6. The emergence of genotypic divergence and future precision medicine applications
7. Lessons from other fields of medicine, Part 1: Breast cancer
8. Lessons from other fields of medicine, Part 2: Cystic fibrosis
9. Lessons learned from evolving frameworks in adult glioblastoma
Part 2 Pitfalls in Definitions, Cohorts, and Measures of Progression
10. Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
11. The theoretical problems of "prodrome? and "phenoconversion? in neurodegeneration
12. The dilemma between milestones of progression vs. clinical scales in Parkinson disease
13. Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer Disease and synucleinopathies
14. Challenges in the study of individuals at risk for Parkinson disease
15. The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms
1. The definition of precision medicine in neurodegenerative disorders and the one disease-many-diseases tension
2. Models of precision medicine for neurodegeneration
3. Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration
4. Mixed pathology as a rule, not exception: Time to reconsider disease nosology?
5. Neurodegenerative disorders: From clinicopathology convergence to systems biology divergence
6. The emergence of genotypic divergence and future precision medicine applications
7. Lessons from other fields of medicine, Part 1: Breast cancer
8. Lessons from other fields of medicine, Part 2: Cystic fibrosis
9. Lessons learned from evolving frameworks in adult glioblastoma
Part 2 Pitfalls in Definitions, Cohorts, and Measures of Progression
10. Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
11. The theoretical problems of "prodrome? and "phenoconversion? in neurodegeneration
12. The dilemma between milestones of progression vs. clinical scales in Parkinson disease
13. Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer Disease and synucleinopathies
14. Challenges in the study of individuals at risk for Parkinson disease
15. The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
